About Galderma & Photocure ASA

Metvix® and Aktilite® are registered trademarks of PhotoCure ASA, the developers of Metvix®.  PhotoCure ASA is responsible for the marketing and sales of Metvix® in the Nordic countries and Galderma is responsible for the marketing and sales of Metvix® in the rest of the world.

Below is a list of countries where Metvix is approved for use - please contact you local office for local prescribing information by clicking here:

Australia
Austria
Belgium
Brazil
Czech Republic
Denmark
Finland
Germany
Greece
Hungary
Ireland
Italy
Luxembourg
Malta
Netherlands
Poland
Portugal
Slovakia
Slovenia
South Africa
Spain
Sweden
Switzerland
United Kingdom
United States
Norway

GALDERMA

Galderma is one of the world's leading pharmaceutical companies focusing exclusively on meeting the needs of dermatology patients, and physicians, by providing innovative products and solutions for the diagnosis, prevention and treatment of dermatological conditions. The company's expertise spans a broad spectrum of diseases of skin, hair and nails.

Created in 1981, Galderma is a joint venture between Nestlé and L'Oréal, and its parent company is based in Switzerland. It deploys a worldwide network of exclusive sales agents and has 33 wholly-owned subsidiaries. Galderma Corporate Services offices are in Paris-La Défense.

Galderma's ongoing development is anchored in its portfolio of highly successful dermatological products that are today marketed in more than 65 countries.

The company is leading the way with a number of fast-growing therapeutic areas following the acquisition or licensing of several strategic products, such as Metvix® for the treatment of non-melanoma skin cancer  using non-invasive photodynamic therapy.

Today number one in dermatology, Galderma's mission is to offer innovative therapeutic solutions that improve patient's lives.

Key Figures:

  • Galderma is number 1 in dermatology  (source: IMS Health, IMS dataview - D class - MAT Q4 2005 - 35 countries).
  • The company has 2,500 employees, 33 subsidiaries on five continents as well as state-of-the-art R&D and manufacturing facilities worldwide
  • Galderma's research efforts have allowed it to issue 1,500 scientific publications, develop more than 150 inventions and file 2,800 patents.

PHOTOCURE ASA

PhotoCure ASA is a Norwegian pharmaceutical company founded in 1993 and listed on the Oslo Stock Exchange. The company develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technologies, targeting key dermatology and oncology markets. PhotoCure has two products with sales and marketing approvals: Metvix®, which is a product developed for the treatment of skin cancer (basal cell carcinoma and in situ squamous cell carcinoma) and pre-cancerous skin lesions (actinic keratosis), and Hexvix®, which is developed for the detection of bladder cancer. Both products are based on the same photodynamic technology, combining the drug known as a photosensitiser with a light source that activates the photosensitiser. PhotoCure is currently testing both products for new indications and aims to develop a pipeline of follow-on products and technologies.

PhotoCure, the PhotoCure logo, Metvix and Hexvix are trademarks or registered trademarks of PhotoCure ASA.